New insider activity at Fulgent Genetics ( (FLGT) ) has taken place on August 26, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Recent transactions in Fulgent Genetics stock saw President & COO Jian Xie selling 696 shares, amounting to $14,964. Additionally, CSO Hanlin Gao sold 548 shares, totaling $11,782.
Recent Updates on FLGT stock
In the last 24 hours, Fulgent Genetics has seen mixed analyst actions following its Q2 2025 earnings report. UBS upgraded the stock to Buy, citing potential growth in the Precision Diagnostics unit and recovery in the Anatomic Pathology segment, which is no longer a drag on growth. They anticipate sustained revenue growth of 10% from 2025 onwards. Conversely, Piper Sandler lowered their price target due to the quarterly results, maintaining a Neutral rating. The earnings report highlighted a 16% year-over-year core revenue growth, driven by gains in Precision Diagnostics and Biopharma Services, despite a GAAP loss of $19 million. The company raised its full-year revenue guidance, reflecting optimism about its strategic advancements and market expansions.
Spark’s Take on FLGT Stock
According to Spark, TipRanks’ AI Analyst, FLGT is a Neutral.
Fulgent Genetics’ overall stock score is driven by strong technical indicators and positive earnings call highlights, such as revenue growth and product expansion. However, financial performance challenges, particularly in profitability and cash flow, and a negative valuation score due to losses, weigh down the overall score.
To see Spark’s full report on FLGT stock, click here.
More about Fulgent Genetics
YTD Price Performance: 16.88%
Average Trading Volume: 273,233
Technical Sentiment Signal: Hold
Current Market Cap: $659M